Argo Biopharma to Present Positive Phase II Interim Results of siRNA Therapeutic BW-20805 for HAE at the 2026 AAAAI Annual Meeting
PR Newswire —
-Poster Presentation Selected as Late Breaking Abstract- SHANGHAI and BOSTON, Feb. 25, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as a late breaking abstract to present...